Skip to main content

NEW YORK (TheStreet) -- Shares of drug developer NephroGenex  (NRX) skyrocketed more than 285% to a 52-week high of $17.98 on Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.

The company is evaluating the drug pyridorin in a late-stage trial in patients with diabetic nephropathy, a chronic and degenerative kidney disease caused by diabetes and often tied to heart disease.

NephroGenex said it has noted cardiac safety concerns with other therapies currently in development.

Exclusive Report:Jim Cramer’s Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Recommends

Pyridorin attempts to work on the underlying cause of diabetic nephropathy, which affects approximately 6 million Americans, in order to slow its progression.

More than 12.8 million shares had changed hands as of 11:26 a.m., which dwarfed the daily average volume of 12,733.

NRX data by YCharts

Image placeholder title

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.